Deutsch English Français

Contact

EP3186377

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3186377

EP3186377 - MODIFIED DOUBLE-STRANDED RNA AGENTS [Right-click to bookmark this link]
Status	The application has been withdrawn Status updated on 13.11.2020 Database last updated on 08.04.2026
Former	Examination is in progress Status updated on 27.04.2018
Former	Request for examination was made Status updated on 02.06.2017
Former	The international publication has been made Status updated on 21.03.2017
Most recent event Tooltip	13.11.2020	Withdrawal of application	published on 16.12.2020 [2020/51]
Applicant(s)	For all designated states Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US
	[2017/27]
Inventor(s)	01 / MAIER, Martin 300 Third Street Cambridge, MA 02142 / US
	02 / FOSTER, Don 300 Third Street Cambridge, MA 02142 / US
	03 / MILSTEIN, Stuart 300 Third Street Cambridge, MA 02142 / US
	04 / KUCHIMANCHI, Satya 300 Third Street Cambridge, MA 02142 / US
	05 / JADHAV, Vasant 300 Third Street Cambridge, MA 02142 / US
	06 / RAJEEV, Kallanthottathil 300 Third Street Cambridge, MA 02142 / US
	07 / MANOHARAN, Muthiah 300 Third Street Cambridge, MA 02142 / US
	08 / PARMAR, Rubina 300 Third Street Cambridge, MA 02142 / US
	[2017/27]
Representative(s)	Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
	[2017/27]
Application number, filing date	15754100.4	14.08.2015
	[2017/27]
	WO2015US45407
Priority number, date	US201462039507P	20.08.2014 Original published format: US 201462039507 P
	US201462083744P	24.11.2014 Original published format: US 201462083744 P
	US201462093919P	18.12.2014 Original published format: US 201462093919 P
	[2017/27]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2016028649
	Date:	25.02.2016
	Language:	EN
	[2016/08]
	Type:	A1 Application with search report
	No.:	EP3186377
	Date:	05.07.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 25.02.2016 takes the place of the publication of the European patent application.
	[2017/27]
Search report(s)	International search report - published on:	EP	25.02.2016
Classification	IPC:	C12N15/113, A61K31/713, A61K47/50, C07H21/00	[2017/27]
	CPC:	C12N15/113 (EP,CN,IL,KR,US); A61K31/713 (IL,KR); A61P43/00 (EP,IL); C12N15/111 (IL,US); C12N2310/14 (EP,CN,IL,KR,US); C12N2310/313 (IL,US); (+) C12N2310/315 (IL,KR); C12N2310/32 (EP,CN,IL,US); C12N2310/321 (IL,KR); C12N2310/322 (IL,KR); C12N2310/3231 (EP,CN,IL,KR,US); C12N2310/332 (EP,CN,IL,KR,US); C12N2310/335 (IL,US); C12N2310/344 (EP,CN,IL,KR,US); C12N2310/346 (EP,CN,IL,KR,US); C12N2310/351 (EP,CN,IL,KR,US); C12N2310/533 (EP,CN,IL,US); C12N2320/51 (EP,CN,IL,KR,US); C12N2320/52 (EP,CN,IL,KR,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/27]
Extension states	BA	20.03.2017
	ME	20.03.2017
Title	German:	MODIFIZIERTE DOPPELSTRÄNGIGE RNA-WIRKSTOFFE	[2017/27]
	English:	MODIFIED DOUBLE-STRANDED RNA AGENTS	[2017/27]
	French:	AGENTS D'ARN DOUBLE BRIN MODIFIÉ	[2017/27]
Entry into regional phase	20.03.2017	National basic fee paid
	20.03.2017	Designation fee(s) paid
	20.03.2017	Examination fee paid
Examination procedure	17.03.2017	Date on which the examining division has become responsible
	20.03.2017	Examination requested [2017/27]
	09.10.2017	Amendment by applicant (claims and/or description)
	26.04.2018	Despatch of a communication from the examining division (Time limit: M06)
	29.08.2018	Observations by third parties
	29.10.2018	Reply to a communication from the examining division
	12.02.2019	Despatch of a communication from the examining division (Time limit: M06)
	21.08.2019	Reply to a communication from the examining division
	04.11.2020	Application withdrawn by applicant [2020/51]
	06.11.2020	Cancellation of oral proceeding that was planned for 26.11.2020
	26.11.2020	Date of oral proceedings (cancelled)
Divisional application(s)	EP20203314.8 / EP3808846
	EP20203754.5 / EP3812462
	EP25172177.5
Fees paid	Renewal fee
	28.08.2017	Renewal fee patent year 03
	27.08.2018	Renewal fee patent year 04
	27.08.2019	Renewal fee patent year 05
	27.08.2020	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[Y] WO2013074974 (ALNYLAM PHARMACEUTICALS INC et al.)
		[AD] WO2010011895 (ALNYLAM PHARMACEUTICALS INC et al.)
		[A] WO2014025805 (ALNYLAM PHARMACEUTICALS INC et al.)
		[A] WO2011109427 (ALNYLAM PHARMACEUTICALS INC et al.)
		[AD] WO2011133876 (ALNYLAM PHARMACEUTICALS INC et al.)
		[YD] CHOUNG S ET AL: "Chemical modification of siRNAs to improve serum stability without loss of efficacy", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 342, no. 3, 14 April 2006 (2006-04-14), pages 919 - 927, XP024923668, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2006.02.049 DOI: http://dx.doi.org/10.1016/j.bbrc.2006.02.049
		[A] J. B. BRAMSEN ET AL: "A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity", NUCLEIC ACIDS RESEARCH, vol. 37, no. 9, 1 May 2009 (2009-05-01), pages 2867 - 2881, XP055000747, ISSN: 0305-1048, DOI: 10.1093/nar/gkp106 DOI: http://dx.doi.org/10.1093/nar/gkp106
		[A] LAURSEN A B ET AL: "Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo", MOLECULAR BIOSYSTEMS, vol. 6, no. 5, 1 May 2010 (2010-05-01), pages 862 - 870, XP002645276, ISSN: 1742-206X, DOI: 10.1039/B918869J DOI: http://dx.doi.org/10.1039/b918869j
		[AD] WALT F. LIMA ET AL: "Single-Stranded siRNAs Activate RNAi in Animals", CELL, vol. 150, no. 5, 1 August 2012 (2012-08-01), US, pages 883 - 894, XP055224162, ISSN: 0092-8674, DOI: 10.1016/j.cell.2012.08.014 DOI: http://dx.doi.org/10.1016/j.cell.2012.08.014
		[A] H. ADDEPALLI ET AL: "Modulation of thermal stability can enhance the potency of siRNA", NUCLEIC ACIDS RESEARCH, vol. 38, no. 20, 1 November 2010 (2010-11-01), pages 7320 - 7331, XP055001288, ISSN: 0305-1048, DOI: 10.1093/nar/gkq568 DOI: http://dx.doi.org/10.1093/nar/gkq568
	Examination	JIE ZHENG ET AL: "Single modification at position 14 of siRNA strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation", THE FASEB JOURNAL, vol. 27, no. 10, 1 October 2013 (2013-10-01), US, pages 4017 - 4026, XP055665143, ISSN: 0892-6638, DOI: 10.1096/fj.13-228668 [D] DOI: http://dx.doi.org/10.1096/fj.13-228668
	by applicant	WO2011133876
		WO2010011895
		WO2007091269
		US7858769
		WO2010141511
		WO2007117686
		WO2009014887
		WO2011031520
		WO9637194
		US4897355
		US5171678
		US5283185
		WO9400569
		WO9324640
		WO9116024
		WO9839359
		US1861608
		US1861108
		US3974808
		US4708708
		US5152808
		US2007080331
		US5328470
		US2013084576
		WO2008100447
		FIRE ET AL., NATURE, vol. 391, 1998, pages 806 - 811
		ELBASHIR ET AL., GENES DEV, vol. 15, 2001, pages 188 - 200
		RAND ET AL., CELL, vol. 123, 2005, pages 621
		LEUSCHNER ET AL., EMBO REP., vol. 7, 2006, pages 314
		SCHWARZ ET AL., CURR. BIOL., vol. 14, 2004, pages 787
		MORRISSEY ET AL., HEPATOLOGY, vol. 41, 2005, pages 1349
		MUHONEN ET AL., CHEMISTRY & BIODIVERSITY, vol. 4, 2007, pages 858 - 873
		CHOUNG ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 342, 2006, pages 919 - 927
		MIKHAILOV, TETRAHEDRON LETTERS, vol. 26, no. 17, 1985, pages 2059
		FLUITER ET AL., MOL. BIOSYST., vol. 10, 2009, pages 1039
		SUBBARAO ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 2964 - 2972
		VOGEL ET AL., J. AM. CHEM. SOC., vol. 118, 1996, pages 1581 - 1586
		TURK ET AL., BIOCHEM. BIOPHYS. ACTA, vol. 1559, 2002, pages 56 - 68
		LAM ET AL., NATURE, vol. 354, 1991, pages 82 - 84
		ZITZMANN ET AL., CANCER RES., vol. 62, 2002, pages 5139 - 43
		AOKI ET AL., CANCER GENE THERAPY, vol. 8, 2001, pages 783 - 787
		HAUBNER ET AL., JOUR. NUCL. MED., vol. 42, 2001, pages 326 - 336
		SIMEONI ET AL., NUCL. ACIDS RES., vol. 31, 2003, pages 2717 - 2724
		SOUTSCHEK ET AL., NATURE, vol. 432, 2004, pages 173 - 178
		FEIGNER, P. L. ET AL., PROC. NATL. ACAD. SCI., vol. 8, 1987, pages 7413 - 7417
		BANGHAM ET AL., M. MOL. BIOL., vol. 23, 1965, pages 238
		OLSON ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 557, 1979, pages 9
		SZOKA ET AL., PROC. NATL. ACAD. SCI., vol. 75, 1978, pages 4194
		MAYHEW ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 775, 1984, pages 169
		KIM ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 728, 1983, pages 339
		FUKUNAGA ET AL., ENDOCRINOL., vol. 115, 1984, pages 757
		MAYER ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 858, 1986, pages 161
		ZHOU ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 19, 1992, pages 269 - 274
		FEIGNER, J. BIOL. CHEM., vol. 269, 1994, pages 2550
		NABEL, PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 11307
		NABEL, HUMAN GENE THER., vol. 3, 1992, pages 649
		GERSHON, BIOCHEM., vol. 32, 1993, pages 7143
		STRAUSS, EMBO J., vol. 11, 1992, pages 417
		ROSOFF: "Pharmaceutical Dosage Forms", vol. 1, 1988, pages: 245
		FELGNER, P. L. ET AL., PROC. NATL. ACAD. SCI., USA, vol. 8, 1987, pages 7413 - 7417
		GAO, X.; HUANG, L., BIOCHIM. BIOPHYS. RES. COMMUN., vol. 179, 1991, pages 280
		ZHOU, X. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1065, 1991, pages 8
		WEINER ET AL., JOURNAL OF DRUG TARGETING, vol. 2, 1992, pages 405 - 410
		DU PLESSIS ET AL., ANTIVIRAL RESEARCH, vol. 18, 1992, pages 259 - 265
	MANNINO, R. J. AND; FOULD-FOGERITE, S., BIOTECHNIQUES, vol. 6, 1988, pages 682 - 690
	ITANI, T. ET AL., GENE, vol. 56, 1987, pages 267 - 276
	NICOLAU, C. ET AL., METH. ENZ., vol. 149, 1987, pages 157 - 176
	STRAUBINGER, R. M.; PAPAHADJOPOULOS, D., METH. ENZ., vol. 101, 1983, pages 512 - 527
	WANG, C. Y.; HUANG, L., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7851 - 7855
	RIEGER: "Pharmaceutical Dosage Forms", 1988, MARCEL DEKKER, INC., pages: 285
	CHEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 3054 - 3057
	WHITTAKET ET AL.: "Stereoselective synthesis of highly functionalized P-stereogenic nucleosides via palladium-catalyzed P-C cross-coupling reactions", TETRAHEDRON LETTERS, vol. 49, 2008, pages 6984 - 87
	ZHAO; CARUTHERS: "Synthesis and Preliminary Biochemical Studies with 5'-Deoxy-5'-methylidyne Phosphonate Linked Thymidine Oligonucleotides", TETRAHEDRON LETTERS, vol. 37, no. 35, 1996, pages 6239 - 42
	LIMA ET AL.: "Single-Stranded siRNAs Activate RNAi in Animals", CELL, vol. 150, 2012, pages 883 - 894
	PRAKASH ET AL.: "Identification of metabolically stable 5-phosphate analogs that support single-stranded siRNA activity", NUCLEIC ACIDS RESEARCH, vol. 43, 2015, pages 2993 - 3011
	WEITZER ET AL.: "The human RNA kinase hClpl is active on 3' transfer RNA exons and short interfering RNAs", NATURE, vol. 447, 2007, pages 222 - 226
	KUROSU ET AL.: "Synthetic studies towards the identification of novel capuramycin analogs with mycobactericidal activity", HETEROCYCLES, vol. 77, 2009, pages 217 - 225
	KUROSU ET AL.: "Concise Synthesis of Capuramycin", ORG. LETT., vol. 11, 2009, pages 2393 - 2396
	ALEIWI ET AL.: "A reliable Pd-mediated hydrogenolytic deprotection of BOM group of uridine ureido nitrogen", TETRAHEDRON LETT., vol. 53, 2012, pages 3758 - 3762

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.